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Abstract The ternary complex of Lactobacillus casei dihydro-
folate reducíase (DHFR) with folate and NADP+ exists as a 
mixture of three interconverting forms (I, Ha and lib) whose 
relative populations are pH dependent, with an effective pÄ" of 
approx. 6. To investigate the role of Asp26 in this pH dependence 
we have measured the T3C chemical shifts of [2,4a,7,9-l3C4lfolate 
in its complex with the mutant DHFR Asp26 -> Asn and NADP+. 
Only a single form of the complex is detected and this has the 
characteristics of form I, an enol form with its Nl unprotonated. 
A study of the pH dependence of the 13C chemical shifts of 
DHFR selectively labelled with [4-13C]aspartic acid in its 
complex with folate and NADP+ indicates that no Asp residue 
has a pÄ" value greater than 5.4. Two of the Asp CO^ signals 
appear as non-integral signals with chemical shifts typical of non-
ionised COOH groups and with a pH dependence characteristic 
of the slow exchange equilibria previously characterised for 
signals in forms I and lib (or Ha). It is proposed that the 
protonation/deprotonation controlling the equilibria involves the 
0 4 position of the folate and that Asp26 influences this indirectly 
by binding in its CO^ form to the protonated Nl group of folate 
in forms I and I la thus reducing the pK involving protonation at 
the 0 4 position to approx. 6. These findings indicate that, in 
forms I and Ha of the ternary complex, folate binds to DHFR in 
a very similar way to methotrexate. 
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1. Introduction 
Dihydrofolate reductase (DHFR) (EC 1.5.1.3) catalyses the 
reduction of 7,8-dihydrofolate (and folate with lower effi-
ciency) to 5,6,7,8-tetrahydrofolate in an NADPH-linked reac-
tion. The enzyme is of continuing pharmacological interest as 
the target for antifolate drugs such as trimethoprim (antibac-
terial) and methotrexate (anti-cancer) which act by inhibiting 
dihydrofolate reductase in parasitic and malignant cells [1]. 
There have been several detailed studies of the mechanism 
and kinetics of the enzyme and also extensive X-ray and 
NMR studies of the structures of its complexes with inhibitors 
and substrates (reviewed in [1-5]). 
Studies of the stereochemistry of the reduction of folate and 
dihydrofolate showed that the orientation of the pteridine ring 
of the substrate in the catalytically functional complex differs 
Corresponding author. Fax: (44) (181) 906 4477. 
1 Present address: Division of Biochemistry and Molecular Biology, 
John Curtin School of Medical Research, Australian National 
University, Canberra, ACT 0200, Australia. 
by approx. 180° from that of the inhibitor methotrexate [6-8] 
and this was confirmed by X-ray diffraction studies of com-
plexes of folate with mammalian and bacterial dihydrofolate 
reductases [9-11]. NMR studies have also revealed that the 
ternary complex of Lactobacillus casei DHFR with folate and 
NADP+ exists as a mixture of three interconverting forms 
whose relative populations are pH-dependent [12-14]. Two 
of the forms (designated forms I and Ha) have the same pter-
idine ring orientation as that observed in the DHFR-metho-
trexate complex while the third (form lib) has the pteridine 
ring turned over by approx. 180°. The latter orientation is 
referred to as the 'active' conformation since this orientation 
would lead to the observed stereochemistry for the enzyme-
catalysed reduction. Recent NMR studies of specifically Re-
labelled folate [15] have indicated that in forms I and Ha of 
the DHFR-folate-NADP+ complex the pterin is in the enolic 
tautomeric form, whereas in the 'active' form lib it is in the 
keto form, as observed for uncomplexed folate at pH 5.5 (see 
Fig. 1). Proposals for the catalytic mechanism of DHFR have 
suggested that keto-enol tautomerism of the substrate may be 
involved [11,16] giving added interest to the study of these 
equilibria in the DHFR-folate-NADP+ complex. 
The variation in the relative proportions of forms I, Ha and 
lib of this complex as a function of pH has been studied using 
:H-, 3H-, 13C-, l oN- and 31P-NMR measurements on the com-
plex formed with wild-type enzyme [12-14]. *H studies of the 
complex formed with the Asp26 -> Asn mutant enzyme showed 
that it exists in only one conformational form (resembling 
form I) and no spectral changes were observed on changing 
the pH over the range 5.4-7.0 [17]. This clearly implicated 
Asp26 (a residue conserved in all bacterial dihydrofolate re-
ductases) in the pH dependence of the conformational equi-
libria observed in complexes with the wild-type enzyme, and it 
was suggested that this pH dependence might arise from the 
protonation and deprotonation of Asp26. 
We now report further 13C-NMR studies of the L. casei 
DHFR-folate-NADP+ complex, using both 13C-labelled sub-
strate and enzyme, aimed at establishing clearly the origin of 
the pH dependence of the conformational equilibrium and the 
tautomeric and ionisation states of the substrate in this com-
plex. 
2. Materials and methods 
The preparation and purification of [2,4a,7,9-13Ci]folate [15], of the 
Asp26 -»Asn mutant of L. casei DHFR [17] and of [4-13C]Asp-labelled 
wild-type DHFR [18] have been described previously. Folate and 
NADP+ were obtained from Sigma Chemical Co. The complex of 
[2,4a,7,9-13C4]folate and NADP+ with DHFR was prepared as de-
scribed previously [15]. The complex of folate and NADP+ with 
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[4-13C]Asp-DHFR was formed by adding 2 molar equivalents of each 
ligand to ensure that the enzyme was wholly in the form of the 
DHFR-folate-NADP+ complex; the enzyme concentration (deter-
mined by absorbance measurements) was 0.5-0.7 mM. The NMR 
samples were dissolved in 90% H2O/10% 2Fl20 containing 50 mM 
potassium phosphate and 200 mM KC1. pH adjustments were made 
by making 2 ¡0.1 additions of concentrated HC1 to the protein solutions 
and measuring the pH using a Corning Model 155 pH meter. The pH 
values are meter readings uncorrected for the small isotope effect due 
to the 10% 2H20. NMR spectra were recorded at 293K using Bruker 
AMX600 and Varian 400 NMR spectrometers. The 13C spectra were 
referenced to external tetramefhylsilane using methods described by 
Cheung and co-workers [15]. 
3. Results and discussion 
In our earlier studies of the DHFR-folate-NADP+ com-
plex, we showed that the pH dependence of the relative pop-
ulations of the three forms of the complex could be accounted 
for either by the simple ionisation of a group with pAT~ 6 or 
by a model in which an ionisable group has pK< 5 in forms 
Ha and lib, and pK> 7 in form I [13,14]. In order to test the 
hypothesis that this ionisable group might be that of Asp26 
[14,17], we have used 13C-NMR to examine directly the 
charge states of the aspartic acid residues of the enzyme in 
the complex with the wild-type enzyme and the tautomeric 
and ionisation states of folate in the ternary complex with 
the Asp26 -> Asn mutant. 
3.1. Ionisation states of the aspartic acid residues 
The 13C-NMR spectra of the ternary complex of folate and 
NADP+ with DHFR selectively labelled with [4-13C]aspartic 
acid were measured as a function of pH over the range pH 
4.6-7.0. Fig. 2 shows representative spectra obtained for the 
complex at different pH values and Fig. 3 displays the pH 
dependence of the chemical shifts of the Asp y-carbon (car-
boxyl) resonances. As one would expect for Asp residues, the 
13C chemical shifts of most of the signals are dependent on 
pH over the range pH 4.6-6.2, but none of them show chem-
ical shift changes over the range pH 6.2-7.0. Some signals 
around 176 ppm arise from 13C at natural abundance present 
in non-enriched residues in the protein. In studies on Esche-
richia coli ribonuclease H, the 13C signals of Asp y-carbons 
were found to appear between 176 and 179 ppm in the de-
protonated state and between 173 and 175 ppm in the proto-
nated state [19]. 
Although the specific assignments of these resonances to the 
15 Asp residues of the protein, and particularly the assign-
ment of the Asp26 resonance*2' are not known, several useful 
observations can be made. We can predict the behaviour ex-
pected of the resonance of Asp26 if this is indeed the residue 
whose ionisation controls the pH dependence of the confor-
mational equilibrium between forms I and (Ila+IIb). In the 
simplest model, it would have a pK of ~ 6 [13,14], but this 
can be eliminated since the pH dependence of the y-13C reso-
nances indicates that no Asp residue has a pK greater than 
5.4. In the alternative model the chemical shift in form I, 
which predominates at low pH and has pK>l, should be 
P> We have attempted to assign the Asp26 signal by examining a 
complex of folate with the mutant Asp26 -> Asn DHFR labelled 
with [4-13C]aspartic acid: the experiments indicated that the Asp26 
signal does not fall outside of the overlapped region 177.0 to 179.5 
ppm. 
characteristic of the carboxyl (-CO2H) state, while in forms 
Ha and lib, which predominate at high pH and have pK< 5, 
the chemical shift will be that of the carboxylate (—CO^) 
state; interconversion between these forms is slow, so that 
changes in resonance intensity, rather than chemical shift, as 
a function of pH are expected. 
It can be seen in Figs. 2 and 3 that three y-carbon 13C 
signals show no change in chemical shift over the range pH 
4.6-7.0: one of these (at 175.7 ppm) is present over the com-
plete pH range whereas two others (179.0 and 177.9 ppm) are 
of non-integral intensity and are detectable only over parts of 
the range. The 13C signal at 175.7 ppm is present at the same 
position and with the same intensity over the complete titra-
tion range; it is therefore unlikely to arise from a residue 
involved in the conformational equilibria in the DHFR-fo-
late-NADP+ complex. It may arise from the carboxylate car-
bon of Asp25 which forms a salt bridge with His153 [20]; the 
pK of His153 is > 8.0 [21], and one would correspondingly 
expect a low pK for Asp25. Of the remaining resonances, 
that at 177.9 ppm is seen only between pH 5.6 and 7.0 its 
intensity decreasing as the pH decreases, whereas in contrast 
the resonance at 179.0 ppm is seen only at low pH values and 
its intensity decreases as the pH increases from pH 4.6 to 5.1. 
Although this is the behaviour expected for the changes in 
intensity of the Asp26 resonance in form Ha or lib (177.9 
ppm signal), and in form I (179.0 ppm signal) the chemical 
shifts of both of these signals are in the range expected for an 
unprotonated 13CO¡" [19]. 
These 13C experiments thus indicate that in the low pH 
form (form I) of the complex Asp26 remains unprotonated 
over the pH range in which this form is observable*3'. The 
same is, however, true for Asp26 in the high pH state of the 
complex (forms Ha and lib). Thus, although the effects of the 
Asp26 -> Asn mutation [17] clearly implicate Asp26 in the pH 
dependence of the conformational equilibria in the DHFR-
folate-NADP+ complex, it cannot be involved directly, since 
it has the same carboxylate charge state in the different forms 
of the complex. 
3.2. The ionisation and tautomeric states of folate in its 
complex with NADP+ and the Asp26 -> Asn DHFR mutant 
In order to understand the effects of the Asp26 -> Asn mu-
tation on the conformational equilibria, the tautomeric and 
ionisation states of the bound folate in the ternary 
Asp26 -* Asn DHFR-folate-NADP+ complex have been exam-
ined by studying the 13C spectra of the complex formed with 
[2,4a,7,9-13C4]folate. 
The 13C spectra of this ternary complex were recorded at 
pH 5.7 and pH 7.0 (see Fig. 4a,b). At each pH, a single signal 
was detected for each labelled site, corresponding to the pres-
ence of a single conformational form, and there were no dif-
ferences in chemical shift or relative intensity of the signals at 
the two pH values. A comparison of these chemical shifts with 
those observed previously for [2,4a,7,9-13C4]folate in its ter-
nary complex with NADP+ and wild-type DHFR (shown in 
Fig. 4c) confirmed that the single form of the complex with 
*3' This is supported by the 'H chemical shifts of the a- and ß-
protons of Asp26 in form I [15] which are almost identical to those 
in the DHFR-methotrexate complex where Asp26 is thought to remain 
unprotonated at pH 5 [22]. 
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Protonation of folate in ternary complex with wild type DHFR and NADP+ 
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Fig. 1. The structures and tautomeric forms of folate: free at pH 5.5, complexed to wild-type DHFR and NADP+ (forms I, Ila and lib) and 
complexed to Asp26 -> Asn DHFR and NADP+. The net charges of the complexes are indicated. 
Asp26 -»Asn DHFR most closely resembles form I of the 
wild-type complex, in agreement with the conclusions from 
the earlier XH studies [17]. 
Cheung and co-workers [15] have estimated the 13C chem-
ical shifts for various tautomeric states of folate and Fig. 4 
includes a schematic diagram showing the predicted 13C 
chemical shifts for the C2 and C4a carbons in various tauto-
meric forms; estimated shifts were not obtained for the C7 
carbons due to the lack of suitable model compounds [15]. 
181 180 179 178 177 176 
13C Chemical shift (ppm) 
175 
Fig. 2. Part of the 150.8 MHz 13C-NMR spectrum at 293 K of the 
1:1:1 complex of folate and NADP+ with [4-13C]Asp DHFR at pH 
values (a) 4.6, (b) 5.1, (c) 6.1 and (d) 6.5. The resonances assigned 
to Asp26 in forms I and lib of the complex are indicated. 
The 13C chemical shift most characteristic of form I is that of 
C4a (124.5 ppm in the Asp26 -> Asn DHFR complex and 
123.9 ppm in the wild-type DHFR complex). These values 
compare favourably with the predicted 13C chemical shifts 
for C4a in various models of the enol tautomer of folate 
(123.3 to 125.7 ppm; Fig. 4), whereas the C4a chemical shifts 
in forms Ila and lib of the wild-type complex are 130 ±2 and 
129.5 ppm, respectively. The chemical shift of the C2 carbon 
(162.3 ppm) in the ternary complex with Asp26 -> Asn DHFR 
is somewhat further downfield than the value observed for 
form I in the wild-type ternary complex (159.8 ppm). Consid-
eration of the estimated chemical shifts for various models 
shown schematically in Fig. 4 indicates that this shift differ-
175 
176 
8 177 
O 
178 
179 
Fig. 3. The pH titration curves for the 13C chemical shifts of the 
[4-13C]Asp residues in the 1:1:1 complex of folate and NADP+ 
with [4-13C]Asp DHFR at 293 K. 
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Fig. 4. Low-field region of the 100.6 MHz 13C-NMR spectra of 
[2,4a,7,9-13C4] folie acid in its 1:1:1 ternary complex with NADP+ 
and L. casei DHFR (a) formed with Asp26->Asn DHFR at pH 7.0 
and 281 K; (b) formed with Asp26^Asn DHFR at pH 5.7 and 281 
K, and (c) formed with the wild-type DHFR at pH 5.6 and 281 K 
(the latter taken from Cheung and co-workers [15]). The figure also 
includes a schematic diagram showing the structures of various keto 
and enolic forms of folate with their predicted 13C chemical shifts 
for the C2 and C4a carbons (from Cheung and co-workers [15]). 
protonated (Fig. 1). These two forms thus differ only in the 
position of a proton on the pterin ring - on N l in form Ha, 
and on N3 in form lib - explaining the observation that the 
Ila/IIb ratio is independent of pH. This tautomerisation is 
accompanied by a change in the orientation of the pterin 
ring, so that the Asp26 carboxylate can form hydrogen bonds 
to Nl-H and 2-NH2 in form Ha, and to N3-H and 2-NH2 in 
form lib. These assignments of the tautomeric and ionisation 
states of folate imply that there is a difference of one proton 
between the folate structure in form I and those in forms Ha 
and lib in the ternary complex with the wild-type DHFR 
(Fig. 1). This would provide a simple explanation for the 
observed pH dependence of the relative populations of forms 
I and II. 
If this is the origin of the pH dependence, then there must 
be a mechanism by which the presence of Asp26 as a carbox-
ylate anion throughout the pH range (pH 5 to 7) influences 
the ionisation of the folate molecule so that the effective pK of 
the folate is approx. 6 in the wild-type enzyme but > 8 in the 
Asp26->Asn mutant. The most likely mechanism is through 
an effect on the pÄ: of Nl of folate. In free folate the pK 
associated with protonation on N l is 2.4, but, in its complex 
with DHFR and NADP+, the proximity of the carboxylate of 
Asp26 and the possibility of ion-pair formation increases this 
pK so that Nl is protonated in forms I and Ha. This proto-
nation on Nl has the effect of decreasing the pK for loss of a 
proton from N3/04 from the value of 8.3 in free folate (for 
deprotonation of N3 in the keto tautomer [23]) to approx. 6 
in the DHFR-folate-NADP+ complex. In the case of 
Asp 2 6 ^Asn DHFR, the replacement of the carboxylate by 
a carboxamide favours binding of folate unprotonated at N l 
(Fig. 1), and the pK of 0 4 in this species is sufficiently high 
that deprotonation of the enolic group is not observed in the 
accessible pH range. 
These results thus indicate that the binding of folate in form 
I of the DHFR-folate-NADP+ complex (see Fig. 1) closely 
parallels the binding of the inhibitor methotrexate: the orien-
tation in the binding site is the same, and methotrexate is also 
protonated on Nl when bound to the wild-type enzyme but 
unprotonated when bound to the Asp26->Asn mutant (see 
Fig. 1) [16,24]. There is a further parallel between the 
DHFR-folate-NADP+ complex and the catalytically function-
al DHFR-dihydrofolate-NADPH complex, since in both cases 
Asp26 appears to determine the pH dependence indirectly, 
through its influence on the pK of groups in the pterin ring 
(Nl and 0 4 in the case of folate, N5 in the case of dihydro-
folate) [11,16,25]. 
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ence could be explained if Nl of folate is unprotonated in 
form I of the Asp 2 6 ^Asn DHFR complex but protonated 
in form I of the wild-type DHFR complex (see Fig. 1), the 
estimated shift for an Nl unprotonated enol model being 
161.4 ppm. 
Cheung and co-workers [15] concluded that for the ternary 
wild-type DHFR complex in form lib folate is present as the 
keto tautomer with Nl unprotonated, while in form Ha, folate 
is most probably present as the enolate tautomer with Nl 
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